

## Novel small molecule drugs to treat high cholesterol

Nyrada Inc (ASX:NYR) is a pre-clinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. Nyrada has two main programs: a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. The company was formed in 2017 by Noxopharm (ASX:NOX), which remains the largest shareholder, and listed on the ASX in January 2020 after raising \$8.5m at \$0.20/CHES Depository interests (CDIs) to give a market capitalisation of \$21.8m (excluding restricted CDIs). The company subsequently raised \$11.5m in June 2021 to fund Phase I trials for both programmes. The company has recently announced exploratory analysis results from its *in vivo* cholesterol efficacy study in a specialised transgenic mouse model (APOE\*3-Leiden.CETP) to evaluation NYX-PCSK9i in combination with a statin. Over the study period, NYX-PCSK9i reduced total cholesterol by 65% when dosed in combination with the statin drug Lipitor<sup>R</sup> and by 46% as a monotherapy, compared with the reduction achieved using Lipitor<sup>R</sup> alone of 27%. Nyrada has selected NYX-PCSK9i as the preferred compound for safety pharmacology and toxicology studies to commence in CY2021, with a Phase I, first-in-human study expected to commence in mid-CY2022.

### Business model

Nyrada is pursuing two main drug development programmes: a cholesterol-lowering drug, NYX-PCSK9i, and a drug to treat brain injury, NYR-BI01. The two FDA-approved PCSK9 inhibitors are potent monoclonal antibody drugs, that lower LDL (“bad”) cholesterol by targeting the protein PCSK9 to reduce the degradation of LDL receptors, which act to remove LDL cholesterol from the bloodstream. Nyrada is aiming to develop the first oral, small molecule PCSK9 inhibitor that can be taken in pill form. NYX-PCSK9i is intended to be used in conjunction with or without a statin drug, the standard cholesterol-lowering medication. The PCSK9 inhibitor drugs currently available are expensive and need to be injected bi-weekly or monthly. Nyrada’s NYR-BI01 is advancing in a collaboration study with the Walter Reed Army Institute (WRAIR) and University of NSW, Sydney, for its brain injury program, validating the potential of its drug candidates. The company has noted that NYR-BI01 is a more potent and improved version of its predecessor, NYX-1010. Nyrada’s business model is to focus on discovery and early-stage drug development i.e., Phase I/II clinical trials, and after safety and efficacy has been confirmed, seek to on-sell or out-licence its drug candidates to established pharma companies.

### Advancing the pathway to Phase I clinical trials

Nyrada noted that in FY21 it had advanced its preclinical programs with R&D expenditure of \$2.2m versus \$1.4m in FY20. Nyrada is focused on completing the remaining studies ahead of commencing a first-in-human trial for its cholesterol-lowering Program in mid-2022. As part of these preparations, the company will be conducting safety pharmacology and toxicology studies in the interim. A pharmacokinetic study showed NYR-BI01 crossed the blood-brain-barrier at above therapeutic levels which means it can reach the area of the brain damaged by traumatic brain injury. Nyrada anticipates testing of NYR-BI01 in WRAIR’s TBI animal model later in 2021, with initial results expected before the end of the year.

### Listed peers are early stage with novel technologies

An independent review of peers by acuity Technology Management which was published in the Chimeric Therapeutics’ November 2020 prospectus highlighted AdAlta, Chimeric, Nyrada, Prescient and Exopharm as the closest Australian-listed peers based on their early stage. Other peers include Argenica and Neuroscientific Pharmaceuticals.

## Pharmaceuticals & Biotech

10<sup>th</sup> September 2021

### Share details

ASX Code	NYR
Share price	\$0.275
Market Capitalisation	\$42.9M
CDIs listed on issue	122.9M
CDIs restricted (unlisted)	33.1M
Net cash at 30/06/2021	\$13.8M
Free float	48.96%

### Share performance (12 months)



### Upside Case

- Exploratory analysis results from *in vivo* cholesterol efficacy study promising
- Well-funded for Phase I trials
- Large potential markets for both programs

### Downside Case

- Very early stage and pre-clinical
- Further equity raisings likely
- No guarantee of success in trials or licencing

### Catalysts/upcoming events

Safety pharmacology & toxicology studies of NYX-PCSK9i commence in 2H CY21

Phase I clinical trials to commence in mid- 2022

### Comparable companies (Aust/NZ)

Argenica (ASX:AGN), AdAlta (ASX:1AD), Cellmid (ASX:CDY) Chimeric Therapeutics (ASX:CHM) Neuroscientific Pharmaceuticals (ASX:NSB), Prescient (ASX:PTX), Exopharm (ASX:EX1)

### Top 5 shareholders

Noxopharm Ltd	21.39%
Altnia Holding (I Dixon Family A/C)	6.36%
Sunset Capital Management	1.63%
Colin Housley & Freda Housley	1.19%
Kohen Enterprises	1.11%

### Company contacts

Laura Vize (Investor Relations Manager) +61 417 026 056  
info@nyrada.com

### RaaS Advisory contacts

Finola Burke +61 414 354 712  
finola.burke@raasgroup.com



# FINANCIAL SERVICES GUIDE

**RaaS Advisory Pty Ltd**

**ABN 99 614 783 363**

**Corporate Authorised Representative, number 1248415**

**of**

**BR SECURITIES AUSTRALIA PTY LTD**

**ABN 92 168 734 530**

**AFSL 456663**

**Effective Date: 6<sup>th</sup> May 2021**



### **About Us**

BR Securities Australia Pty Ltd (BR) is the holder of Australian Financial Services License (“AFSL”) number 456663. RaaS Advisory Pty Ltd (RaaS) is an Authorised Representative (number 1248415) of BR.

This Financial Service Guide (FSG) is designed to assist you in deciding whether to use RaaS’s services and includes such things as

- who we are
- our services
- how we transact with you
- how we are paid, and
- complaint processes

Contact Details, BR and RaaS

BR Head Office: Level 14, 344 Queen Street, Brisbane, QLD, 4000

RaaS. 20 Halls Road Arcadia, NSW 2159

P: +61 414 354712

E: [finola.burke@raasgroup.com](mailto:finola.burke@raasgroup.com)

RaaS is the entity providing the authorised AFSL services to you as a retail or wholesale client.

**What Financial Services are we authorised to provide?** RaaS is authorised to

- provide general advice to retail and wholesale clients in relation to
  - Securities
- deal on behalf of retail and wholesale clients in relation to
  - Securities

The distribution of this FSG by RaaS is authorized by BR.

### **Our general advice service**

Please note that any advice given by RaaS is general advice, as the information or advice given will not take into account your particular objectives, financial situation or needs. You should, before acting on the advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Prospectus, Product Disclosure Statement or like instrument. As we only provide general advice we will not be providing a Statement of Advice. We will provide you with recommendations on securities

### **Our dealing service**

RaaS can arrange for you to invest in securities issued under a prospectus by firstly sending you the offer document and then assisting you fill out the application form if needed.

### **How are we paid?**

RaaS earns fees for producing research reports. Sometimes these fees are from companies for producing research reports and/or a financial model. When the fee is derived from a company, this is clearly highlighted on the front page of the report and in the disclaimers and disclosures section of the report.

We may also receive a fee for our dealing service, from the company issuing the securities.

### **Associations and Relationships**

BR, RaaS, its directors and related parties have no associations or relationships with any product issuers other than when advising retail clients to invest in managed funds when the managers of these funds may also be clients of BR. RaaS’s representatives may from time to time deal in or otherwise have a financial interest in financial products recommended to you but any material ownership will be disclosed to you when relevant advice is provided.

### **Complaints**

If you have a complaint about our service you should contact your representative and tell them about your complaint. The representative will follow BR’s internal dispute resolution policy, which includes sending you a copy of the policy when required to. If you aren’t satisfied with an outcome, you may contact AFCA, see below. BR is a member of the Australian Financial Complaints Authority (AFCA). AFCA provide fair and independent financial services complaint resolution that is free to consumers.

Website: [www.afca.org.au](http://www.afca.org.au); Email: [info@afca.org.au](mailto:info@afca.org.au); Telephone: 1800931678 (free call)

In writing to: Australian Financial Complaints Authority, GPO Box 3, Melbourne, VIC, 3001.

### **Professional Indemnity Insurance**

BR has in place Professional Indemnity Insurance which satisfies the requirements for compensation under s912B of the Corporations Act and that covers our authorized representatives.

## DISCLAIMERS and DISCLOSURES

This report has been prepared and issued by RaaS Advisory Pty Ltd trading as Research as a Service (“RaaS”). This research is issued in Australia by RaaS and any access to it should be read in conjunction with the Financial Services Guide on the preceding two pages. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. Opinions contained in this report represent those of the principals of RaaS Advisory at the time of publication. RaaS Advisory provides this financial advice as an honest and reasonable opinion held at a point in time about an investment’s risk profile and merit and the information is provided by the RaaS Advisory in good faith. The views of the adviser(s) do not necessarily reflect the views of the AFS Licensee. RaaS Advisory has no obligation to update the opinion unless RaaS Advisory is currently contracted to provide such an updated opinion. RaaS Advisory does not warrant the accuracy of any information it sources from others. All statements as to future matters are not guaranteed to be accurate and any statements as to past performance do not represent future performance. RaaS Advisory’s principals, employees and associates may hold shares in companies that are covered and, if so, this will be clearly stated on the front page of each report.

Assessment of risk can be subjective. Portfolios of equity investments need to be well diversified and the risk appropriate for the investor. Equity investments in listed or unlisted companies yet to achieve a profit or with an equity value less than \$50 million should collectively be a small component of a balanced portfolio, with smaller individual investment sizes than otherwise.

The science of climate change is common knowledge and its impacts may damage the global economy. Mitigating climate change may also disrupt the global economy. Investors need to make their own assessments and we disclaim any liability for the impact of either climate change or mitigating strategies on any investment we recommend.

Investors are responsible for their own investment decisions, unless a contract stipulates otherwise. RaaS Advisory does not stand behind the capital value or performance of any investment. Subject to any terms implied by law and which cannot be excluded, RaaS Advisory shall not be liable for any errors, omissions, defects or misrepresentations in the information (including by reasons of negligence, negligent misstatement or otherwise) or for any loss or damage (whether direct or indirect) suffered by persons who use or rely on the information. If any law prohibits the exclusion of such liability, RaaS Advisory limits its liability to the re-supply of the Information, provided that such limitation is permitted by law and is fair and reasonable. Copyright 2021 RaaS Advisory Pty Ltd (A.B.N. 99 614 783 363). All rights reserved.